Synvista Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1986-01-01
- Employees
- 11
- Market Cap
- -
- Website
- https://www.alteon.com
Clinical Trials
13
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
Efficacy and Safety of Topical ALT-2074 (SYI-2074) for Treatment of Chronic Plaque Psoriasis
- Conditions
- Psoriasis
- Interventions
- Drug: 4,4-dimethyl-benziso-2H-selenazineDrug: Placebo
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2009-01-30
- Lead Sponsor
- Synvista Therapeutics, Inc
- Target Recruit Count
- 30
- Registration Number
- NCT00782613
- Locations
- 🇮🇱
Ha'emek Medical Center, Afula, Israel
🇮🇱Kaplan Medical Center, Rechovot, Israel
🇮🇱Chaim Sheba Medical Center, Tel Hashomer, Israel
Safety & Efficacy of ALT-711 (Alagebrium) in Chronic Heart Failure
- First Posted Date
- 2008-08-22
- Last Posted Date
- 2009-01-30
- Lead Sponsor
- Synvista Therapeutics, Inc
- Target Recruit Count
- 100
- Registration Number
- NCT00739687
- Locations
- 🇺🇸
University of Alabama Hospital, Birmingham, Alabama, United States
🇺🇸Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
Beginning a Randomized Evaluation of the AGE Breaker Alagebrium in Diastolic Heart Failure (BREAK-DHF-I)
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2009-01-30
- Lead Sponsor
- Synvista Therapeutics, Inc
- Target Recruit Count
- 160
- Registration Number
- NCT00662116
Study of Alagebrium in Patients With Insulin-Dependent Type 1 Diabetes and Microalbuminuria
- Conditions
- Diabetes Mellitus, Type 1Diabetic Nephropathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2009-01-30
- Lead Sponsor
- Synvista Therapeutics, Inc
- Target Recruit Count
- 80
- Registration Number
- NCT00557518
- Locations
- 🇦🇺
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
🇦🇺International Diabetes Institute, Caulfield, Victoria, Australia
🇦🇺Dept. of Clinical and Biomedical Science Myers House, Geelong, Victoria, Australia
The BENEFICIAL Study: Evaluating the Efficacy and Safety of Alagebrium (ALT-711) in Patients With Chronic Heart Failure
- First Posted Date
- 2007-08-15
- Last Posted Date
- 2010-01-13
- Lead Sponsor
- Synvista Therapeutics, Inc
- Target Recruit Count
- 100
- Registration Number
- NCT00516646
- Locations
- 🇳🇱
Dept. Cardiology - University Medical Center Groningen, Groningen, P.O. Box 30 001, Netherlands
- Prev
- 1
- 2
- 3
- Next